Compare TECX & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TECX | RLMD |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.0M | 319.7M |
| IPO Year | N/A | 2012 |
| Metric | TECX | RLMD |
|---|---|---|
| Price | $21.01 | $4.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $80.40 | $9.00 |
| AVG Volume (30 Days) | 529.5K | ★ 620.1K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $13.70 | $0.24 |
| 52 Week High | $27.64 | $5.12 |
| Indicator | TECX | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 52.15 |
| Support Level | $20.52 | $3.81 |
| Resistance Level | $25.39 | $4.56 |
| Average True Range (ATR) | 2.35 | 0.35 |
| MACD | -0.23 | 0.04 |
| Stochastic Oscillator | 45.94 | 68.39 |
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.